Navigation Links
Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
Date:11/14/2007

Clinical Trial Aimed to Supplement Current Research Findings on the

Treatment of Localized Prostate Cancer

TORONTO, Nov. 14 /PRNewswire/ -- A Canadian study on High Intensity Focused Ultrasound therapy with the Sonablate(R) 500 - a Health Canada approved treatment for localized prostate cancer - is underway at Can-Am HIFU. Through funding from AstraZeneca Canada Inc, Can-Am HIFU, a prostate cancer treatment centre, will conduct an REB/Health Canada approved clinical trial. The objective of the study is to supplement current research findings on safety and efficacy of HIFU therapy in the treatment of localized prostate cancer. The trial will measure both the biochemical (PSA) cure rates and the Biopsy-proven cure rates at one year.

"AstraZeneca is committed to promoting excellence in Canadian health science research and to supporting the growth of Canada's scientific community," says Marc Zarenda, Scientific Director - Oncology at AstraZeneca Canada Inc. "We are excited to put our support behind this clinical trial."

The nation-wide study will involve a select number of men and will be led by Can-Am HIFU urologists Jack Barkin, MD; Laurence Klotz, MD; Sender Herschorn, MD; Neil Fleshner, MD; Michael Robinette, MD; Antonio Finelli, MD; and Sidney Radomski, MD. The study will play an integral role in building Canadian data on HIFU therapy.

Currently, the data on HIFU are from studies conducted in other countries," said Dr. Barkin, Chief of Staff, Humber River Regional Hospital and Director of Can-Am HIFU. "As more patients are considering HIFU as an alternative treatment option for prostate cancer, we recognize the need to build Canadian data on HIFU therapy."

HIFU has been used in several countries for a number of years to treat men with localized prostate cancer and benign prostatic hyperplasia. The therapy uses ultrasound energy to heat and destroy specifically targeted areas of the prostate. HIFU was approved for use in the treatment of prostate cancer in Canada in June 2005. Can-Am HIFU urologists have been treating patients from Canada and abroad on an out-patient basis since March 2006. Currently the Sonablate(R) 500 is undergoing clinical trials in the United States and has not been approved for U.S. marketing by the FDA.

For more information on the study please contact Can-Am HIFU at 1 -877- 787-5906. For more information on HIFU with the Sonablate(R) 500, please visit http://www.internationalhifu.com

About Can-Am HIFU

Can-Am HIFU is a Canadian entity of USHIFU, LLC. The clinic, located in Toronto, was established in March 2006 and solely treats localized prostate cancer using HIFU with the Sonablate(R) 500. Can-Am HIFU physicians include Jack Barkin, MD; Laurence Klotz, MD; Sender Herschorn, MD; Neil Fleshner, MD; Michael Robinette, MD; Antonio Finelli, MD; and Sidney Radomski, MD.

About USHIFU

USHIFU, LLC is a development company headquartered in Charlotte, NC. USHIFU is the exclusive distributor of the Sonablate(R) 500 in North, South and Central America, the island nations of the Caribbean and South Africa. The company holds a minority ownership position in Focus Surgery Inc. of Indianapolis, the world leader in the development of HIFU products and the manufacturer of the Sonablate(R) 500 in conjunction with Misonix, Inc (MSON).


'/>"/>
SOURCE USHIFU, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medivir AB (Nasdaq ... a new Board of Directors that will be submitted ... Committee comprises representatives of the company,s three largest shareholders ... who have accepted a seat on the Nomination Committee, ... the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... 2016" report to their offering. ... The latest research Autism Spectrum Disorder Drugs ... benchmarks in the global Autism Spectrum Disorder market. The research ... the key drugs marketed for Autism Spectrum Disorder and their clinical ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified ... year ended 31 December 2016 compared with the previous corresponding period. ... viewed here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: ... 2015: $15.7m; up 11%) Profit before tax of ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... The Smart Machine Age is here, and it’s disrupting everything. ... of all jobs in the United States may be taken over by technology in ... aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will belong ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users ... X . Users have total control over position, rotation, distortion, edge softness, edge blur, ... Final Cut Pro X. , With ProGlass Prism users are given the tools ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Department of Justice jointly issued a letter to withdraw previous guidance ... with their gender identity. The guidance issued in May 2016 by the Obama ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):